ALS

Peer-reviewed publications demonstrate Modality.AI’s commitment to advancing ALS research. 

These publications provide insights into speech, facial, and motor biomarkers, showcasing how our multimodal analytics platform enhances clinical trials and deepens scientific understanding of ALS progression. Our collaborations with leading institutions and biopharma partners underscore the rigor and impact of our technology, reflecting our dedication to improving outcomes for patients and caregivers alike.

Featured publications:

1. Multimodal speech biomarkers for remote monitoring of ALS disease progression

2. Multimodal speech-based biomarkers outperform the ALS-FRS in predicting individual disease progression in ALS

3. Computer vision-based assessment of limb motor function in ALS using remote monitoring of activities of daily living

4. Canonical Timing Alignment of read speech in ALS is correlated with perceived speech impairment and listener effort

Many additional publications can be found at: https://modality.ai/publications/als  

We're pleased to share lessons learned from clinical trials, and highlight emerging trends in ALS assessment and management through discussions, conference talks, and interactive sessions led by our team and our collaborators from research institutions and biopharma.  

Modality.AI is proud to collaborate with leading academic institutions, biotech and pharmaceutical companies, and patient advocacy groups dedicated to advancing ALS research and patient care. Our partnerships leverage combined expertise, resources, and shared visions to drive breakthroughs in understanding disease progression, accelerating drug development, and enhancing patient outcomes. 

Follow our progress as we continue to innovate, collaborate, and deliver meaningful contributions to the ALS community.

1. Kely Norel: Assessment of speech intelligibility for remote tracking of ALS progression 

2. Webinar: ALS Caregiving, Technology, and Trial Inclusion

3. Modality Research Scientist Michael Neumann, PhD Presents at ENCALS

4. Announcing Results from Verge Genomics Proof-of-Concept ALS Clinical Trial

5. Advancing Research with Target ALS

6. Target ALS Webinar with Amy Easton, Senior Director of Scientific Programs

7. Modality to Present at 35th International Symposium on ALS/MND

8. Five New ALS Publication Acceptances

9. Target ALS and Modality.AI Collaborate in Multimodal Study of ALS

10. A Turning Point in ALS Trials with Karl Kieburtz, MD, MPH